Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

Inclusion Criteria: * Adult men and women (\>18 years of age) with a diagnosis of neurological conditions such as MS, PD, CVA, myelomeningocele, SCI, or traumatic brain injury longer than 6 months prior to treatment. * Diagnosis of neurogenic bladder indicated for treatment with BTX-A for OAB symptoms. * Participants must be able to provide informed consent, as well as understand and be willing to undergo. follow-up procedures and completion of all questionnaires provided during the study. Exclusion Criteria: * Symptomatic UTI at the time of procedure, defined as positive nitrites or high-volume leukocyte esterase on urine dip in addition to at least one of the following symptoms: dysuria, gross hematuria, suprapubic pain, frequency/urgency above baseline. * Diagnosis of bladder pain syndrome or other chronic pain syndrome including fibromyalgia, chronic pelvic pain, pelvic floor dysfunction, levator myalgia. * Untreated bladder malignancy. * Women who are currently pregnant or breast feeding. * Contraindications to intradetrusor BTX-A injections.